ERYTECH Pharma S.A. Logo

ERYTECH Pharma S.A.

ISIN: FR0011471135 | Ticker: ERYP | LEI: 969500U8ZZCODU8A9374
Sector: Health CareSub-Industry: Biotechnology
Country: France

About ERYTECH Pharma S.A.

Company Description

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH’s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival.

The Company’s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cell’s altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of first-line triple-negative breast cancer.

Year founded

2004

Served area

Worldwide

Headquarters

60 Avenue Rockefeller, 69008 Lyon – France

Financial statements

Download as Excel
Line item in (eur) 01.01.2019 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Assets N/A 118,545,000.00 80,402,000.00 66,768,000.00 45,811,000.00
Noncurrent Assets N/A 36,962,000.00 30,770,000.00 26,720,000.00 3,177,000.00
Property Plant And Equipment N/A 25,632,000.00 20,862,000.00 18,960,000.00 393,000.00
Intangible Assets Other Than Goodwill N/A 603,000.00 589,000.00 15,000.00 5,000.00
Other Noncurrent Assets N/A 718,000.00 1,091,000.00 876,000.00 195,000.00
Current Assets N/A 81,583,000.00 49,632,000.00 40,048,000.00 42,634,000.00
Inventories N/A 358,000.00 0.00 0.00 0.00
Current Trade Receivables N/A 36,000.00 4,000.00 12,000.00 76,000.00
Cash and cash equivalents N/A 73,173,000.00 44,446,000.00 33,699,000.00 38,789,000.00
Other Current Assets N/A 8,016,000.00 5,182,000.00 6,337,000.00 3,769,000.00
Equity And Liabilities N/A 118,545,000.00 80,402,000.00 66,768,000.00 45,811,000.00
Equity 145,602,000.00 85,560,000.00 26,539,000.00 22,845,000.00 N/A
Issued Capital N/A 1,794,000.00 2,006,000.00 3,102,000.00 3,102,000.00
Retained Earnings Profit Loss For Reporting Period N/A N/A -73,300,000.00 -53,797,000.00 -228,000.00
Retained Earnings Excluding Profit Loss For Reporting Period N/A N/A -24,616,000.00 -25,293,000.00 -29,765,000.00
Share Premium N/A 281,688,000.00 120,705,000.00 97,618,000.00 48,975,000.00
Other Reserves N/A -136,607,000.00 -24,616,000.00 -25,293,000.00 N/A
Equity Attributable To Owners Of Parent N/A 85,560,000.00 26,539,000.00 22,845,000.00 23,487,000.00
Noncurrent Liabilities N/A 13,105,000.00 24,516,000.00 23,918,000.00 10,646,000.00
Noncurrent Provisions N/A 506,000.00 652,000.00 524,000.00 419,000.00
Deferred Tax Liabilities N/A 0.00 0.00 0.00 0.00
Noncurrent Derivative Financial Liabilities N/A 0.00 288,000.00 0.00 0.00
Longterm Borrowings N/A 1,321,000.00 14,379,000.00 15,232,000.00 7,547,000.00
Current Liabilities N/A 19,880,000.00 29,347,000.00 20,005,000.00 11,678,000.00
Current Provisions N/A 71,000.00 0.00 0.00 314,000.00
Trade And Other Current Payables N/A 13,775,000.00 20,910,000.00 14,154,000.00 5,115,000.00
Current Derivative Financial Liabilities N/A 0.00 129,000.00 0.00 0.00
Other Current Liabilities N/A 4,510,000.00 4,436,000.00 3,870,000.00 2,909,000.00
Current Borrowings And Current Portion Of Noncurrent Borrowings N/A 99,000.00 2,265,000.00 164,000.00 2,565,000.00
Line item in (eur) 01.01.2019/
01.01.2020
01.01.2020/
01.01.2021
01.01.2021/
01.01.2022
01.01.2022/
01.01.2023
Revenue 0.00 0.00 0.00 N/A
Revenue From Contracts With Customers N/A 0.00 0.00 0.00
Other Income 5,283,000.00 3,718,000.00 4,180,000.00 30,998,000.00
Profit Loss From Operating Activities -64,074,000.00 -68,832,000.00 -56,515,000.00 -2,796,000.00
Finance Income 2,947,000.00 889,000.00 5,422,000.00 4,453,000.00
Finance Costs 1,533,000.00 5,354,000.00 2,702,000.00 1,364,000.00
Income Tax Expense Continuing Operations -1,000.00 3,000.00 2,000.00 521,000.00
Profit (loss) -62,659,000.00 -73,300,000.00 -53,797,000.00 -228,000.00
Line item in (eur) 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Profit (loss) -62,659,000.00 -73,300,000.00 -53,797,000.00 -228,000.00
Adjustments For Income Tax Expense -1,000.00 3,000.00 2,000.00 521,000.00
Adjustments For Decrease Increase In Inventories 1,038,000.00 358,000.00 0.00 0.00
Adjustments For Depreciation And Amortisation Expense 4,216,000.00 4,991,000.00 5,377,000.00 4,619,000.00
Adjustments For Provisions 192,000.00 57,000.00 135,000.00 445,000.00
Adjustments For Unrealised Foreign Exchange Losses Gains N/A 3,028,000.00 -3,570,000.00 -510,000.00
Adjustments For Sharebased Payments 1,359,000.00 1,179,000.00 1,323,000.00 447,000.00
Adjustments For Losses Gains On Disposal Of Noncurrent Assets 42,000.00 22,000.00 17,000.00 -23,893,000.00
Income Taxes Paid Refund Classified As Operating Activities 0.00 0.00 2,000.00 3,000.00
Cash Flows From Used In Operating Activities -43,310,000.00 -51,720,000.00 -56,770,000.00 -31,764,000.00
Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities 0.00 83,000.00 0.00 37,630,000.00
Purchase Of Property Plant And Equipment Classified As Investing Activities 20,117,000.00 1,139,000.00 298,000.00 85,000.00
Purchase Of Intangible Assets Classified As Investing Activities 16,000.00 2,000.00 0.00 0.00
Proceeds From Other Longterm Assets Classified As Investing Activities 414,000.00 4,000.00 145,000.00 N/A
Purchase Of Other Longterm Assets Classified As Investing Activities 119,000.00 421,000.00 192,000.00 N/A
Cash Flows From Used In Investing Activities -19,838,000.00 -1,475,000.00 -345,000.00 38,127,000.00
Proceeds From Issuing Shares 0.00 118,000.00 34,631,000.00 0.00
Proceeds From Issuing Other Equity Instruments 47,000.00 12,000.00 0.00 0.00
Proceeds From Borrowings Classified As Financing Activities 0.00 27,134,000.00 12,157,000.00 3,081,000.00
Repayments Of Borrowings Classified As Financing Activities 738,000.00 62,000.00 0.00 3,081,000.00
Payments Of Lease Liabilities Classified As Financing Activities 978,000.00 1,615,000.00 1,702,000.00 1,545,000.00
Interest Paid Classified As Financing Activities 195,000.00 326,000.00 374,000.00 223,000.00
Other Inflows Outflows Of Cash Classified As Financing Activities 38,000.00 0.00 0.00 N/A
Cash Flows From Used In Financing Activities 40,000.00 25,449,000.00 44,712,000.00 -1,768,000.00
Effect Of Exchange Rate Changes On Cash And Cash Equivalents 1,910,000.00 -981,000.00 1,656,000.00 495,000.00
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes -61,198,000.00 -28,727,000.00 -10,747,000.00 5,090,000.00
Cash and cash equivalents 73,173,000.00 44,446,000.00 33,699,000.00 38,789,000.00

Please note that some sums might not add up.

Filings & Publications

Insider Trades

Date Trading entity / Person Association Trade type Volume
23.06.23 None Other Other EUR 2,255,495.13
23.06.23 None Other Other EUR 43,821.79
23.06.23 None Other Other EUR 33,465.82

Capital markets information

ISIN

FR0011471135

LEI

969500U8ZZCODU8A9374

Sector

Health Care

Industry Group

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Sub-Industry

Biotechnology

Listed Stock Exchange

Euronext Paris

Main Stock Exchange

Contact Investor Relations department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.